Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments
- Monopar announced the commencement of a Phase 1 dosimetry clinical trial for its MNPR-101 Radiopharmaceutical Program targeting uPAR.
- Positive preclinical data suggest significant clinical benefits from MNPR-101 in cancer treatment.
- Biodistribution data using therapeutic radioisotopes conjugated to MNPR-101 showed promising results in tumor elimination.
- The company is enrolling patients in the fifth dose level cohort for its Camsirubicin Phase 1b Dose-Escalation Trial.
- Monopar reported $7.3 million in cash and short-term investments as of December 31, 2023.
- Net loss for the fourth quarter of 2023 was $1.8 million, with Research and Development expenses decreasing.
- General and Administrative expenses slightly increased for the year ended December 31, 2023.
- None.
Insights
The financial results reported by Monopar Therapeutics Inc. indicate a strategic focus on advancing their clinical programs, particularly the MNPR-101 Radiopharmaceutical Program. The reduction in net loss from $10.5 million in 2022 to $8.4 million in 2023 and a decrease in the per-share loss from $0.83 to $0.61, suggests improved cost management and potentially increasing operational efficiency. Moreover, the company's cash position, bolstered by recent capital raises, provides a runway through mid-2025, which is critical for investor confidence as it aligns with the timeline for key clinical milestones.
However, the R&D expenditure decrease, particularly in the Validive and camsirubicin programs, could raise questions about the pace of development and the potential for future value creation from these assets. The increased investment in the MNPR-101 program may signal a strategic pivot or prioritization, which could be a double-edged sword; it may lead to a breakthrough therapy and significant market opportunity, but also represents concentration risk. Investors should monitor the enrollment and progress of the ongoing clinical trials closely as they will be pivotal in determining the company's future valuation and market potential.
The initiation of the MNPR-101 Radiopharmaceutical Program's Phase 1 dosimetry clinical trial is a significant development in the oncology field. The targeting of uPAR in advanced cancers is a novel approach, as uPAR expression is prevalent in aggressive cancer types such as triple-negative breast, colorectal and pancreatic cancers. The use of positron emission tomography (PET) imaging to assess tumor uptake and normal organ biodistribution is a sophisticated technique that can provide detailed insights into the drug's efficacy and safety profile.
Furthermore, the preclinical data showing high specificity and durable tumor uptake, as well as near complete elimination of tumor in xenograft models, are promising. However, it is important to remain cautiously optimistic until the clinical data corroborates these findings. The involvement of an internationally recognized radiopharmaceutical physician adds credibility to the trial, which could increase the likelihood of successful outcomes and eventual FDA approval. If successful, this program could significantly impact treatment paradigms for patients with cancers expressing uPAR.
The biopharmaceutical sector is highly competitive, with investors closely watching clinical trial advancements and financial health indicators. Monopar's recent developments suggest a strategic emphasis on their novel MNPR-101 Radiopharmaceutical Program. The specificity of MNPR-101 in targeting uPAR-expressing tumors presents a unique market niche, especially considering the unmet medical need in aggressive cancers such as triple-negative breast cancer.
Market dynamics for cancer therapeutics favor innovative treatments with strong efficacy and safety profiles. Early positive preclinical data may position Monopar favorably among peers, potentially attracting partnership opportunities or even making the company a takeover target. However, the high costs and risks associated with oncology drug development necessitate a careful analysis of the company's financial sustainability and the scalability of their pipeline. Investors should consider the broader market trends, such as the increasing demand for personalized medicine and targeted therapies, which could enhance the commercial potential of Monopar's programs if they prove successful in human trials.
WILMETTE, Ill., March 28, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced fourth quarter and full-year 2023 financial results and summarized recent developments.
Recent Developments
Novel MNPR-101 Radiopharmaceutical Program targeting uPAR – Phase 1 dosimetry clinical trial to commence in the coming weeks
- MNPR-101-Zr Phase 1 dosimetry clinical trial has Human Research Ethics Committee (HREC) clearance in Australia and is on track to initiate at the Melbourne Theranostic Innovation Centre (MTIC) within the next few weeks.
- Will enroll patients with advanced cancers, aiming for those most likely to have uPAR expression, which include a majority of all triple-negative breast, colorectal, and pancreatic cancers.
- Will utilize state-of-the-art positron emission tomography (PET) imaging to assess tumor uptake, normal organ biodistribution, and safety.
- Internationally recognized radiopharmaceutical physician, Professor Rodney Hicks, will be the lead investigator for the trial.
- Will enroll patients with advanced cancers, aiming for those most likely to have uPAR expression, which include a majority of all triple-negative breast, colorectal, and pancreatic cancers.
- Positive preclinical data support the potential of a MNPR-101 based radiopharmaceutical to provide a very meaningful clinical benefit to patients.
- In February 2024, Monopar shared preclinical biodistribution and efficacy data using imaging and therapeutic radioisotopes conjugated to MNPR-101. Imaging with MNPR-101-Zr in a pancreatic cancer human tumor xenograft mouse model showed high specificity and durable tumor uptake. With the therapeutic radioisotope actinium-225 (Ac-225) conjugated to MNPR-101, near complete elimination of tumor was achieved after a single injection in a triple negative breast human tumor xenograft mouse model.
- In March 2024, Monopar shared biodistribution data using the therapeutic radioisotope Lutetium-177 (Lu-177) conjugated to MNPR-101. The images show highly preferential uptake in tumor, helping explain the near complete elimination of tumors observed after a single injection of therapeutic radioisotopes bound to MNPR-101.
- In February 2024, Monopar shared preclinical biodistribution and efficacy data using imaging and therapeutic radioisotopes conjugated to MNPR-101. Imaging with MNPR-101-Zr in a pancreatic cancer human tumor xenograft mouse model showed high specificity and durable tumor uptake. With the therapeutic radioisotope actinium-225 (Ac-225) conjugated to MNPR-101, near complete elimination of tumor was achieved after a single injection in a triple negative breast human tumor xenograft mouse model.
Camsirubicin – Phase 1b Dose-Escalation Trial, Currently enrolling the Fifth Dose-Level Cohort (650 mg/m2)
- Monopar is presently enrolling patients at the fifth dose level, which is over twice the highest dose reached in any prior camsirubicin clinical trial (650 mg/m2 versus 265 mg/m2).
Results for the Fourth Quarter and Year Ended December 31, 2023, Compared to the Fourth Quarter and Year Ended December 31, 2022
Cash and Net Loss
Cash, cash equivalents and short-term investments as of December 31, 2023, were
Net loss for the fourth quarter of 2023 was
Research and Development (R&D) Expenses
R&D expenses for the fourth quarter of 2023 were
R&D expenses for the year ended December 31, 2023 were
General and Administrative (G&A) Expenses
G&A expenses for the fourth quarter of 2023 were
G&A expenses for the year ended December 31, 2023 were
About Monopar Therapeutics Inc.
Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients. Monopar's pipeline consists of Phase 1b-stage camsirubicin for the treatment of advanced soft tissue sarcoma; Phase 1-stage MNPR-101 for radiopharmaceutical use in various advanced cancers; and an early-stage camsirubicin analog, MNPR-202. For more information, visit: www.monopartx.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of these forward-looking statements include: that Monopar’s Phase 1 dosimetry clinical trial will commence in the coming weeks; that Professor Rodney Hicks, will be the lead investigator for Monopar’s MNPR-101-Zr Phase 1 dosimetry clinical trial; that Professor Hicks will enroll patients at MTIC in Australia; that positive preclinical data to date support the potential of a MNPR-101 based radiopharmaceutical (MNPR-101-RIT) to provide a very meaningful clinical benefit to patients and that Monopar expects that its current funds, including the net proceeds from its at-the-market facility in Q1 2024, will be sufficient for Monopar to continue operations beyond June 30, 2025. The forward-looking statements involve risks and uncertainties including, but not limited to: that we may expend available funds sooner than anticipated or require additional funding due to change in circumstances or unanticipated events; that future preclinical or clinical data will not be as promising as the data to date; not initiating and enrolling the MNPR-101-Zr Phase 1 clinical trial in the coming weeks or at all; that MNPR-101-Zr and/or MNPR-101 conjugated to a therapeutic radioisotope may cause unexpected serious adverse effects or fail to image or be effective against the cancer tumors in humans; and the significant general risks and uncertainties surrounding the research, development, regulatory approval, and commercialization of imaging agents and therapeutics. Actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in Monopar's filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Monopar undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Any forward-looking statements contained in this press release represent Monopar’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.
CONTACT:
Monopar Therapeutics Inc.
Investor Relations
Kim R. Tsuchimoto
Chief Financial Officer
kimtsu@monopartx.com
Follow Monopar on social media for updates:
Twitter: @MonoparTx LinkedIn: Monopar Therapeutics
FAQ
What Phase clinical trial is Monopar initiating for its MNPR-101 Radiopharmaceutical Program?
What did the preclinical data suggest about MNPR-101?
What did the biodistribution data using therapeutic radioisotopes conjugated to MNPR-101 show?
What trial is Monopar currently enrolling patients for?
How much cash and short-term investments did Monopar report as of December 31, 2023?
What was the net loss for the fourth quarter of 2023?
What happened to Research and Development expenses for the fourth quarter of 2023 compared to the same period in 2022?
How did General and Administrative expenses change for the year ended December 31, 2023, compared to the previous year?
